US 7413870
SAK: modulation of cellular proliferation for treatment of cancer
granted A61KA61K2039/505A61K38/00
Quick answer
US patent 7413870 (SAK: modulation of cellular proliferation for treatment of cancer) held by Rigel Pharmaceuticals, Inc. expires Mon Aug 14 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Aug 19 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 14 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K38/00